Drug Profile
Research programme: tryptase inhibitors - Celera Genomics
Latest Information Update: 04 Oct 2006
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Class
- Mechanism of Action Tryptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma
Most Recent Events
- 04 Oct 2006 Discontinued - Preclinical for Allergic rhinitis in USA (PO)
- 04 Oct 2006 Discontinued - Preclinical for Asthma in USA (PO)
- 13 Jun 2005 Data presented at the 101st International Conference of the American Thoracic Society (ATS-2005) have been added to the Obstructive airways disease pharmacodynamics section